Ajuras Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.30 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 27.47%
- Profit Growth 18.75%
- Ebitda -59.71%
- Net Worth 41.38%
- Total Assets 24.11%
About Ajuras Pharmaceuticals
Ajuras Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 December 2018 (Six years and one month 23 days old ). Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Jitendra Kumar, Manish Kumar, and Rupam Kumari serve as directors at the Company.
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909MH2018PTC318865
- Company No.
318865
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ajuras Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rupam Kumari  | Managing Director | 01-Apr-2019 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jitendra Kumar | Director | 28-Dec-2018 | Current |
| Manish Kumar | Director | 28-Dec-2018 | Current |
Financial Performance of Ajuras Pharmaceuticals.
Ajuras Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.47% increase. The company also saw a substantial improvement in profitability, with a 18.75% increase in profit. The company's net worth Soared by an impressive increase of 41.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ajuras Pharmaceuticals?
Unlock access to Ajuras Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ajuras Pharmaceuticals?
Ajuras Pharmaceuticals has a workforce of 15 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ajuras Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ajuras Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.